Showing 1 to 11 of 11 results
CVS Faces Class-Action Lawsuit Over Obesity Drug Coverage
A class-action lawsuit targets CVS Caremark for removing coverage of Eli Lilly's Zepbound, replacing it with Novo Nordisk's Wegovy, despite medical professionals arguing the drugs aren't interchangeable, impacting an estimated 25-30 million people.
CVS Faces Class-Action Lawsuit Over Obesity Drug Coverage
A class-action lawsuit targets CVS Caremark for removing coverage of Eli Lilly's Zepbound, replacing it with Novo Nordisk's Wegovy, despite medical professionals arguing the drugs aren't interchangeable, impacting an estimated 25-30 million people.
Progress
24% Bias Score
Novo Nordisk Offers $499 Ozempic to US Patients
Novo Nordisk is offering Ozempic for $499 per month to US patients paying out-of-pocket, responding to political pressure to lower drug costs and competition from compounding pharmacies.
Novo Nordisk Offers $499 Ozempic to US Patients
Novo Nordisk is offering Ozempic for $499 per month to US patients paying out-of-pocket, responding to political pressure to lower drug costs and competition from compounding pharmacies.
Progress
40% Bias Score
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
Progress
52% Bias Score
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
Progress
56% Bias Score
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Progress
40% Bias Score
Greece Launches New Obesity Drug Amidst Booming Market
Greece launched tirzepatide, a weekly injectable obesity drug costing \"253.05 EUR\", promising \"20%\" weight loss; high demand is expected, reflecting a \"200 billion USD\" market projection by 2030 and innovation in transdermal delivery systems.
Greece Launches New Obesity Drug Amidst Booming Market
Greece launched tirzepatide, a weekly injectable obesity drug costing \"253.05 EUR\", promising \"20%\" weight loss; high demand is expected, reflecting a \"200 billion USD\" market projection by 2030 and innovation in transdermal delivery systems.
Progress
44% Bias Score
Ozempic Mouth: A New Beauty Concern Emerges from Weight-Loss Drugs
The increasing use of weight-loss drugs like Ozempic is causing a new cosmetic concern dubbed "Ozempic mouth," characterized by changes in facial structure leading to an aged or sunken smile appearance due to fat loss in the cheeks and jawline, alongside various oral health issues like dry mouth and...
Ozempic Mouth: A New Beauty Concern Emerges from Weight-Loss Drugs
The increasing use of weight-loss drugs like Ozempic is causing a new cosmetic concern dubbed "Ozempic mouth," characterized by changes in facial structure leading to an aged or sunken smile appearance due to fat loss in the cheeks and jawline, alongside various oral health issues like dry mouth and...
Progress
56% Bias Score
UK Weight-Loss Injections Linked to Pancreatitis Cases
Over a million people in the UK have used weight loss and diabetes jabs, with the Medicines and Healthcare products Regulatory Agency (MHRA) reporting 294 cases of pancreatitis (inflammation of the pancreas) linked to these drugs, including five deaths. A new study will investigate genetic links.
UK Weight-Loss Injections Linked to Pancreatitis Cases
Over a million people in the UK have used weight loss and diabetes jabs, with the Medicines and Healthcare products Regulatory Agency (MHRA) reporting 294 cases of pancreatitis (inflammation of the pancreas) linked to these drugs, including five deaths. A new study will investigate genetic links.
Progress
48% Bias Score
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Progress
36% Bias Score
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
Progress
52% Bias Score
Virta Health's 60% Revenue Surge Driven by Employer Demand for Cost-Effective Weight Loss Solutions
Virta Health, a digital diabetes and weight loss program, achieved 60% revenue growth in 2024, exceeding $100 million, due to increasing employer demand for cost-effective alternatives to expensive GLP-1 drugs; the company's nutrition-focused approach leads to an average 13% weight loss in a year, e...
Virta Health's 60% Revenue Surge Driven by Employer Demand for Cost-Effective Weight Loss Solutions
Virta Health, a digital diabetes and weight loss program, achieved 60% revenue growth in 2024, exceeding $100 million, due to increasing employer demand for cost-effective alternatives to expensive GLP-1 drugs; the company's nutrition-focused approach leads to an average 13% weight loss in a year, e...
Progress
40% Bias Score
Showing 1 to 11 of 11 results